DODayane Andriotti Otta

Dayane Andriotti Otta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dayane Andriotti Otta has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Olindo Assis Martins-Filho

    Fundação Oswaldo Cruz, Brasil

    3 shared publications
  • A. Camila Corsini

    Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br

    1 shared publication
  • A. P. Daniel de Miranda

    Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br

    1 shared publication
  • Alice Timponi Franca

    Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, MG, Brazil

    1 shared publication
  • Ana Carolina Campi-Azevedo

    Integrated Biomarker Research Group Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br

    1 shared publication
  • Ana Maris Carlesso

    Universidade Federal do Rio Grande do Sul

    1 shared publication

Latest Publications

  • Open Access

    Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil

    by Sarah Vieira Contin, B. F. Nathalie Almeida, S. Priscilla Filgueiras, A. Camila Corsini, A. P. Daniel de Miranda, J. Wander de Jeremias, A. Olindo Martins-Filho, Andrea Teixeira-Carvalho, Ana Carolina Campi-Azevedo, A. Dayane Otta, et al.

    This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.

  • Open Access

    Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia

    by André Rolim Belisário, Franciane Mendes-Oliveira, Valquíria Reis de Souza, Eduarda Bolina-Santos, Fabíola Gomes Mendes, Elizabeth Castro Moreno, Alice Timponi Franca, Ester Cerdeira Sabino, Dayane Andriotti Otta, Elaine Speziali de Faria, et al.


  • Open Access

    Identification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity

    by Dayane Andriotti Otta, Fernanda Fortes de Araújo, Vitor Bortolo de Rezende, Elaine Maria Souza-Fagundes, Silvana Maria Elói-Santos, Matheus Fernandes Costa-Silva, Raiany Araújo Santos, Heloísa Alves Costa, Jair Lage Siqueira-Neto, Olindo Assis Martins-Filho, et al.

    In seeking substitutions for the current Chagas disease treatment, which has several relevant side effects, new therapeutic candidates have been extensively investigated. In this context, a balanced interaction between mediators of the host immune response seems to be a key element for therapeutic success, as a proinflammatory microenvironment modulated by interleukin-10 (IL-10) is shown to be relevant to potentiate anti- Trypanosoma cruzi drug activity. This study aimed to identify the potential immunomodulatory activities of the anti- T. cruzi K777, pyronaridine (PYR), and furazolidone (FUR) compounds in peripheral blood mononuclear cells (PBMC) from noninfected (NI) subjects and chronic Chagas disease (CD) patients. Our results showed low cytotoxicity to PBMC populations, with 50% cytotoxic concentrations (CC 50 ) of 71.0 μM (K777), 9.0 μM (PYR), and greater than 20 μM (FUR). In addition, K777 showed no impact on the exposure index (EI) of phytohemagglutinin-stimulated leukocytes (PHA), while PYR and FUR treatments induced increased EI of monocytes and T lymphocytes at late stages of apoptosis in NI subjects. Moreover, K777 induced a more prominent proinflammatory response (tumor necrosis factor alpha-positive [TNF-α + ] CD8 + /CD4 + , gamma interferon-positive [IFN-γ + ] CD4 + /CD8 + modulated by interleukin-10-positive [IL-10 + ] CD4 + T/CD8 + T) than did PYR (TNF-α + CD8 + , IL-10 + CD8 + ) and FUR (TNF-α + CD8 + , IL-10 + CD8 + ). Signature analysis of intracytoplasmic cytokines corroborated the proinflammatory/modulated (K777) and proinflammatory (PYR and FUR) profiles previously found. In conclusion, the lead compound K777 may induce beneficial changes in the immunological profile of patients presenting the chronic phase of Chagas disease and may contribute to a more effective therapy against the disease.


  • Prevalence of Acanthamoeba spp. (Sarcomastigophora: Acanthamoebidae) in wild populations of Aedes aegypti (Diptera: Culicidae)

    by Dayane Andriotti Otta, Marilise Brittes Rott, Ana Maris Carlesso, Onilda Santos da Silva

    Studies of interrelationship between microorganisms and mosquitoes are of great importance, since it can provide support for better understand related to biology, development and their control. In this way, it is known that mosquito larvae and free-living amoebae (FLA) normally occupy similar aquatic microhabitats. However, few studies have been conducted about such coexistence. For that reason, the objective of the present study was to verify the prevalence of Acanthamoeba spp. in wild populations of Aedes aegypti, as well as to characterize the genotypic lineage, and their possible pathogenicity through thermo- and osmotolerance. Amoebae were investigated in 60 pools, each containing ten larvae of A. aegypti, collected in Porto Alegre (Rio Grande do Sul, Brazil). The Acanthamoeba isolates were morphologically characterized and submitted to the polymerase chain reaction technique to confirm identification of the genus. In addition, genotype analyses as well as tests for presumptive pathogenicity in some samples were performed. Of the 60 pools examined, 54 (90 %) were positive for FLA. Of these isolates, 47 (87 %) belonged to the genus Acanthamoeba. The genotypic groups T4, T3 and T5 were identified, numbering 14 (53.8 %), ten (38.5 %) and two (7.7 %) isolates, respectively. The physiological tests performed with 14 strains showed that 12 (85.7 %) were non-pathogenic, while two (14.3 %) were considered as having low pathogenic potential. These results provide a basis for a better understanding of the interaction between these protozoan and mosquitoes in their natural habitat. This study is the first to report the isolation of Acanthamoeba spp. from wild mosquitoes.